Liisa Bayko
Stock Analyst at Evercore ISI Group
(2.54)
# 557
Out of 5,255 analysts
90
Total ratings
54.41%
Success rate
33.46%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
CRSP CRISPR Therapeutics | Upgrades: Outperform | 60 99 | 38.31 | 158.42% | 2 | Feb 14, 2025 | |
TVTX Travere Therapeutics | Maintains: Outperform | 33 45 | 18.33 | 145.5% | 5 | Feb 12, 2025 | |
BCRX BioCryst Pharma | Maintains: Outperform | 10 12 | 8.39 | 43.03% | 5 | Jan 13, 2025 | |
EDIT Editas Medicine | Maintains: Outperform | 7 5 | 1.53 | 226.8% | 5 | Dec 16, 2024 | |
CARM CARISMA Therapeutics | Downgrades: In-Line | 4 1 | 0.23 | 204.35% | 2 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: In-Line | 7 5 | 3.19 | 56.74% | 3 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 30 35 | 21.3 | 64.32% | 4 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 405 360 | 326.66 | 10.21% | 9 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 210 260 | 251.72 | 3.29% | 1 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: In-Line | 27 2 | 2.67 | -25.09% | 2 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: In-Line | 7 2 | 1.25 | 60% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 37 33 | 6.96 | 374.14% | 4 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 50 38 | 41.05 | -7.43% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Outperform | 438 | 493.96 | -11.33% | 15 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Outperform | 60 80 | 38.05 | 110.25% | 8 | Jun 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 18 | 5.17 | 248.16% | 1 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 14 25 | 5.08 | 392.13% | 1 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Outperform | 62 | 5.59 | 1009.12% | 4 | Jul 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 35 | 5.4 | 548.15% | 1 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 24 | 23.26 | 3.18% | 1 | Jun 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: In-Line | 378 | n/a | n/a | 1 | Mar 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reinstates: Outperform | 30 | 9.74 | 208.01% | 1 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Market Perform | n/a | n/a | n/a | 2 | Mar 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Market Outperform | 10 | 3.29 | 203.95% | 1 | Feb 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Market Outperform | 175 | n/a | n/a | 3 | Jan 30, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Market Outperform | 10 16 | n/a | n/a | 1 | Aug 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Market Perform | 20 | n/a | n/a | 1 | May 19, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Market Perform | n/a | n/a | n/a | 1 | Jan 31, 2017 |